About Axil Capital
Axil Capital is a venture capital firm founded in 2017. It is primarily based out of Minato City, Japan. As of Dec 2025, Axil Capital is an active investor, having invested in 10 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in Japan based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series A round of DT Axis Overall, Axil Capital portfolio has seen 2 IPOs, namely C4 Therapeutics and Frequency Therapeutics. A lot of funds co-invest with Axil Capital, with names like Taiwania Capital sharing a substantial percentage of its portfolio. Axil Capital has team of 7 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio IPOs
Axil Capital's List of Top Investments
Axil Capital has a portfolio of 10 companies. Their most notable investments are in Suono Bio and GEXVal.Their portfolio spans across Japan, United States and Israel. They have invested in Life Sciences, HealthTech, High Tech, across Series A, Series B and 1 more. Here is the list of top investments by Axil Capital:Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
Key facts about C4 Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Annual Revenue: $35.9M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $223M
- Employee Count: 110 as on Apr 30, 2026
- Investors: HTIF, Bain Capital Life Sciences and 27 Others
- Latest Funding Round: Post IPO, Jan 04, 2024, $*****
- Highlight: Public
2. TechsoMed
Developer of ultrasound-based real-time monitoring systems for thermal ablation procedures. Biotrace is an imaging and analysis unit that performs real-time monitoring and controlling of tissue destruction by ablation devices. It interfaces with a standard imaging ultrasound device enabling it to monitor and predict the progression of tissue destruction during an ablation procedure.
Key facts about TechsoMed
- Founded Year: 2012
- Location: Rehovot (Israel)
- Stage: Series B
- Total Funding till date: $9.6M
- Employee Count: 27 as on Apr 30, 2026
- Investors: Mayo Clinic, Johnson & Johnson Innovation and 19 Others
- Latest Funding Round: Series B, Mar 03, 2021, $*****
- Highlight: Editors' Pick
Developing regenerative therapeutic for reversing hearing loss. The company's lead candidate FX-322 for sensorineural hearing loss and remyelination in multiple sclerosis. These small-molecule therapeutics selectively activate progenitor cells already present in the body that helps to create healthy functional tissues and organs.
Key facts about Frequency Therapeutics
- Founded Year: 2015
- Location: Cambridge (United States)
- Annual Revenue: $6.39M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $136M
- Employee Count: 48 as on Feb 28, 2023
- Investors: RTW Investments, Deerfield and 21 Others
- Latest Funding Round: Post IPO, Jul 22, 2020, $*****
- Highlight: Public
4. Suono Bio
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract. The device they have developed can be used for the treatment of inflammatory bowel disease, cancer, and infectious GI conditions. The technology was initiated in the research laboratories at MIT.
Key facts about Suono Bio
- Founded Year: 2015
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $12.7M
- Employee Count: 3 as on Apr 30, 2026
- Investors: Taiwania Capital, Fujifilm and 9 Others
- Latest Funding Round: Series B, Aug 25, 2023, $*****
- Highlight: Editors' Pick
5. Cranebio
Developer of self-service genetic test kits for women health. The company offers a wearable testing and a next-generation genetic rapid kit that applies DNA origami technology to detect visible light nucleic acids focused on hormones and diseases peculiar to women.
Key facts about Cranebio
- Founded Year: 2021
- Location: Minato (Japan)
- Stage: Series A
- Total Funding till date: $1.67M
- Employee Count: 2 as on Apr 30, 2026
- Investors: Axil Capital, Nippon Venture Capital and 1 Other
- Latest Funding Round: Series A, Oct 04, 2023, $*****
Axil Capital's Year-on-Year Investment Trends
Axil Capital has invested in 10 companies over the last 7 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 2 investments. Its most recent first time investment was in DT Axis and most recent follow-on round was in TechsoMed.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 2 | 0 | 2 |
2024 | 0 | 0 | 0 |
2023 | 3 | 0 | 3 |
2022 | 0 | 0 | 0 |
2021 | 1 | 1 | 2 |
2020 | 2 | 0 | 2 |
2019 | 2 | 1 | 3 |
Axil Capital's Investments by Stage
Axil Capital has made 4 investments in Series A stage with an average round size of $5.99M, 4 investments in Series B stage with an average round size of $53.4M and 2 investments in Series C stage with an average round size of $11.6M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 4 |
Series C | 2 |
Note: We have considered here, only first round of investments
Axil Capital's Investments by Sector
Axil Capital has a diverse portfolio, with companies operating in the Life Sciences, HealthTech and High Tech. Notably, it has invested in 10 Tech companies, 8 Enterprise (B2B) companies, 1 Consumer (B2C) company and at least 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
HealthTech | 3 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Axil Capital's Investments by Geography
Axil Capital has made most investments in Japan (6), followed by United States where it has made 3 investments.Country | No. of Investments |
|---|---|
Japan | 6 |
United States | 3 |
Israel | 1 |
Note: We have considered here, only first round of investments
Axil Capital's recent investments
Axil Capital has not made any investment in 2026 so far.Here are the most recent investments by Axil Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 09, 2025 | Japan | Series A | 4842 | - | |
Jan 14, 2025 | Japan | Series B | 1517 | ||
Dec 04, 2023 | Japan | Series C | 2486 | [+3] | |
Oct 04, 2023 | Japan | Series A | 9767 | ||
Jun 06, 2023 | Japan | Series C | 6193 |
IPOs and Publicly Listed companies in Axil Capital's Portfolio
2 of Axil Capital's portfolio companies have become public. C4 Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 at marketcap of $789M and Frequency Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $426M.Here are Axil Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 02, 2020 | Jun 16, 2020 | Series B | 4912 | |
Oct 03, 2019 | Jan 07, 2019 | Series B | 4606 |
Team profile of Axil Capital
Axil Capital has a team of 7 members including 2 Partners, 1 Venture Partner and 2 Principals located in Japan. Axil Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Axil Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Tokyo | - | - | |
Partner | Japan | - | ||
Venture Partner | Tokyo | - | - | |
Principal | Tokyo | - | ||
Principal | Tokyo | - |
Co-investors of Axil Capital
Over the past 7 years, 94 investors have co-invested in Axil Capital's portfolio companies. This includes funds and angels.
- Invested before Axil Capital: Cobro Ventures, DBJ Capital and 26 others have invested in rounds before Axil Capital. There are 2 companies where Cobro Ventures has invested before Axil Capital and 2 companies where DBJ Capital has invested before Axil Capital.
- Top Co-investors of Axil Capital: 36 investors entered a company along with Axil Capital. These include investors like Taiwania Capital (3 companies).
- Invested after Axil Capital: A total of 30 investors have invested in Axil Capital's portfolio after their investments. Top Investors include Nissay Capital (2 companies), Betta Pharmaceuticals (1 company) and Yongjin Group (1 company).
Recent News related to Axil Capital
•
•
•
•
Cancer drug developer LinkMed secures ¥1.5B in Series B funding.Startup Log•Jan 14, 2025•, JIC Venture Growth Investments, Axil Capital, DBJ Capital and 1 other
•
•
Cranebio Co., Ltd. Announcement of Series A financingre-how.net•Oct 04, 2023•Cranebio, Axil Capital, Nippon Venture Capital, Align Capital Partners
•
Cellusion raised 2.83 Billion Yen (USD 21 Million) in Series C RoundBusiness Wire•Jun 07, 2023•Cellusion, JIC Venture Growth Investments, Nissay Capital, SPARX Group and 7 others
•
•
TechsoMed Raises $7M in Series B FinancingFinSMEs•Mar 03, 2021•TechsoMed, Axil Capital, Yongjin Group, Cobro Ventures and 5 others
•
